Haider Alwash, MD
Interventional Cardiology · Galveston, TXNPI 1154685279
Payments from drug & device makers
Across 139 payments — averaging $44.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Abbott$703
- Amgen$500
- W. L. Gore & Associates, Inc.$433
- Biotronik Inc.$384
- Johnson & Johnson$338
- plus $3K from 25 others
What the payments were for
- Travel & lodging$1913%
- Food & beverage$5,86495%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 26 | $1,196 |
| Abbott | 15 | $703 |
| Amgen | 14 | $500 |
| W. L. Gore & Associates, Inc. | 6 | $433 |
| Biotronik Inc. | 6 | $384 |
| Johnson & Johnson | 15 | $338 |
| Inari Medical, Inc. | 3 | $270 |
| Shockwave Medical, Inc | 1 | $214 |
| Actelion Pharmaceuticals US, Inc. | 4 | $167 |
| AstraZeneca | 5 | $165 |
| Abiomed | 2 | $146 |
| Edwards Lifesciences | 1 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $138 |
| Medtronic | 3 | $131 |
| Bolton Medical Inc | 2 | $116 |
| Penumbra, Inc. | 1 | $116 |
| Philips North America LLC | 3 | $115 |
| Lantheus Medical Imaging, Inc. | 2 | $115 |
| Livanova USA, Inc. | 1 | $106 |
| Boehringer Ingelheim | 5 | $95 |
| Angiodynamics, Inc. | 1 | $92 |
| Biosense Webster, Inc. | 1 | $89 |
| Merck | 4 | $80 |
| Pfizer | 4 | $67 |
| Novartis | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Novo Nordisk | 1 | $24 |
| GE HealthCare | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$362
- GORE CARDIOFORM Septal Occluder$295
- AMPLATZER Occluders$267
- Repatha$244
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$214
- SYNERGY$211
- WATCHMAN FLX$149
- HeartMate Touch$137
- Watchman$120
- Indigo System$116
- LifeVest$112
- XARELTO$107
- ProtekDuo$106
- CT THROMBECTOMY SYSTEM KIT$104
How this compares
$6,153 in reported general payments places this provider in the 30th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 139 | $102,381 |
| EliquisApixaban | 128 | $97,999 |
| XareltoRivaroxaban | 87 | $80,203 |
| FarxigaDapagliflozin Propanediol | 39 | $28,080 |
| BrilintaTicagrelor | 40 | $21,838 |
| JardianceEmpagliflozin | 11 | $8,422 |
| VascepaIcosapent Ethyl | 11 | $3,296 |
| Metoprolol Succinate | 171 | $2,147 |
| ClopidogrelClopidogrel Bisulfate | 137 | $1,423 |
| Amiodarone Hcl | 38 | $1,263 |
| Carvedilol | 144 | $1,129 |
| Ezetimibe | 34 | $1,103 |
| Losartan Potassium | 105 | $1,080 |
| Amlodipine Besylate | 140 | $844 |
| Atorvastatin Calcium | 92 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $57 | $102,381139 claims |
| PfizerEliquis | $67 | $97,999128 claims |
| Johnson & JohnsonXarelto | $338 | $80,20387 claims |
| AstraZenecaFarxiga, Brilinta | $165 | $49,91879 claims |
| Boehringer IngelheimJardiance | $95 | $8,42211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Galveston
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.